This week is ISOQOL’s 24th Annual Conference in Philadelphia and this year is quite special for Modus Outcomes, as it will be the first year with Antoine as a member of the Board of Directors.

This prestigious position is a recognition from our peers of our leadership in patient-centered outcomes research and contribution to the development of our field. This appointment just follows a successful meeting with FDA in September where Modus presented its concept-driven measurement approach for evaluating and developing COA instruments (see news below).  This approach is at the core of our method to improve the accuracy and interpretability of COA and better understand and communicate the benefit of treatment to a range of stakeholders.

If you are planning on attending ISOQOL in Philadelphia this year, please feel free to ask Antoine about our concept-driven measurement approach.